(Q45931836)

17 December 2017

title

Salvage therapy with single agent bevacizumab for recurrent glioblastoma. (English)

1 reference

17 December 2017

1 reference

Marc C Chamberlain

1

1 reference

17 December 2017

Sandra K Johnston

series ordinal

2

1 reference

17 December 2017

publication date

11 July 2009

1 reference

17 December 2017

Journal of Neuro-Oncology

published in

1 reference

17 December 2017

volume

96

1 reference

17 December 2017

issue

2

1 reference

17 December 2017

page(s)

259-269

1 reference

17 December 2017

https://scigraph.springernature.com/pub.10.1007/s11060-009-9957-6

exact match

0 references

cites work

Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11060-009-9957-6

Epidemiology of venous thromboembolism in 9489 patients with malignant glioma.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11060-009-9957-6

High-dose cyclophosphamide chemotherapy for recurrent CNS tumors in children

21 January 2018

1 reference

12 December 2020

Intravenous carboplatin for recurrent malignant glioma: a phase II study

1 reference

12 December 2020

Origins of brain tumors--a disease of stem cells?

1 reference

12 December 2020

Radiosurgery as part of the initial management of patients with malignant gliomas

1 reference

12 December 2020

Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab

1 reference

12 December 2020

Imaging‐guided convection‐enhanced delivery and gene therapy of glioblastoma

1 reference

12 December 2020

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

1 reference

12 December 2020

Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial

1 reference

12 December 2020

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

1 reference

12 December 2020

Pathophysiological consequences of VEGF-induced vascular permeability

1 reference

12 December 2020

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

1 reference

12 December 2020

A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.

1 reference

12 December 2020

13-cis-retinoic acid in the treatment of recurrent glioblastoma multiforme

1 reference

12 December 2020

The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review

1 reference

12 December 2020

Incidence of risk of thromboembolism during treatment high-grade gliomas: a prospective study.

1 reference

12 December 2020

alphaPlGF: a new kid on the antiangiogenesis block

1 reference

12 December 2020

Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: A retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy

1 reference

12 December 2020

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

1 reference

12 December 2020

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

12 December 2020

Venous thromboembolism and survival in patients with high-grade glioma

1 reference

12 December 2020

Acidic and basic fibroblast growth factors are present in glioblastoma multiforme

1 reference

12 December 2020

Angiogenesis in gliomas: biology and molecular pathophysiology

1 reference

12 December 2020

A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma

1 reference

12 December 2020

1 reference

12 December 2020

Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy

1 reference

12 December 2020

A comparison of two simple hazard ratio estimators based on the logrank test

1 reference

12 December 2020

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

1 reference

12 December 2020

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group

1 reference

12 December 2020

Irinotecan therapy in adults with recurrent or progressive malignant glioma.

1 reference

12 December 2020

Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases.

1 reference

12 December 2020

Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors

1 reference

12 December 2020

Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme

1 reference

12 December 2020

The future of therapy for glioblastoma

1 reference

12 December 2020

Making a tumour's bed: glioblastoma stem cells and the vascular niche.

1 reference

12 December 2020

Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen

1 reference

12 December 2020

A perivascular niche for brain tumor stem cells

1 reference

12 December 2020

Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain.

1 reference

12 December 2020

Irinotecan in the treatment of glioma patients: current and future studies of the North Central Cancer Treatment Group

1 reference

12 December 2020

A new weapon for attacking tumor blood vessels

1 reference

12 December 2020

Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors

1 reference

12 December 2020

Angiogenesis in brain tumours

1 reference

12 December 2020

Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study

1 reference

12 December 2020

Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation

1 reference

12 December 2020

MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.

1 reference

12 December 2020

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

1 reference

12 December 2020

Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas

1 reference

12 December 2020

The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review

1 reference

12 December 2020

Carboplatin and recurrent childhood brain tumors

1 reference

12 December 2020

Biology and treatment of malignant glioma

1 reference

12 December 2020

Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study

1 reference

12 December 2020

Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor

1 reference

12 December 2020

Treatment of patients with recurrent gliomas with cyclophosphamide and vincristine

1 reference

12 December 2020

Mechanisms of angiogenesis in gliomas

1 reference

12 December 2020

Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors

1 reference

12 December 2020

External irradiation followed by an interstitial high activity iodine-125 implant “boost” in the initial treatment of malignant gliomas: NCOG study 6G-82-2 gliomas: NCOG study 6H-82-2

1 reference

12 December 2020

Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials

1 reference

12 December 2020

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

1 reference

12 December 2020

Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults.

1 reference

12 December 2020

Antiangiogenic therapy for primary and metastatic brain tumors

1 reference

12 December 2020

Interstitial brachytherapy for newly diagnosed patients with malignant gliomas: the UCSF experience

1 reference

12 December 2020

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

1 reference

12 December 2020

1 reference

12 December 2020

Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme

1 reference

12 December 2020

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

1 reference

12 December 2020

VEGF as a therapeutic target in cancer

1 reference

12 December 2020

VEGF inhibition and renal thrombotic microangiopathy

1 reference

12 December 2020

Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers

1 reference

12 December 2020

Antiangiogenic therapy: a universal chemosensitization strategy for cancer?

1 reference

12 December 2020

Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition

1 reference

12 December 2020

Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11.

1 reference

12 December 2020

Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative

1 reference

12 December 2020

Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft.

1 reference

12 December 2020

Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group

1 reference

12 December 2020

Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study

1 reference

12 December 2020

10.1007/S11060-009-9957-6

Identifiers

DOI

1 reference

17 December 2017

Dimensions Publication ID

1040541619

0 references

1 reference

17 December 2017